Bioadhesive sulfacetamide sodium microspheres: Evaluation of their effectiveness in the treatment of bacterial keratitis caused by Staphylococcus aureus and Pseudomonas aeruginosa in a rabbit model

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 72, Issue 3, 2009, Pages 487-495

  Sensoy, Demet ^a   Cevher, Erdal ^a   Sarici, Ahmet ^a   Yilmaz, Mesut ^a   Özdamar, Akif ^a   Bergişadi, Nazan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Bacterial keratitis; Cornea; Microsphere; Mucoadhesion; Pseudomonas aeruginosa; Staphylococcus aureus; Sulfacetamide sodium; Texture analyzer

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; MICROSPHERE; PECTIN; POLYCARBOPHIL; POLYMER; SULFACETAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL VIABILITY; BLEPHARITIS; CLINICAL EFFECTIVENESS; CONJUNCTIVITIS; CONTROLLED STUDY; CORNEA EDEMA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG RESPONSE; ENCAPSULATION; IN VITRO STUDY; IN VIVO STUDY; IRITIS; KERATITIS; MALE; MEAN RESIDENCE TIME; MORPHOLOGICAL TRAIT; MUCOADHESION; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RABBIT; SPRAY DRYING; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYMPTOMATOLOGY; THERMAL STIMULATION;

ADHESIVES; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; KERATITIS; MALE; MICROSPHERES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SULFACETAMIDE;

EID: 67449113544     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.02.006     Document Type: Article

References (51)

1. Kaufman H.E., Barron B.A., and McDonald M.B. The Cornea (1988), Churchill Livingstone, New York, USA 217-247
2. Abbot R.L., Kremer P.A., and Abrams M.A. Bacterial corneal ulcers. In: Tasman N., and Jaeger E.A. (Eds). Duane's Clinical Ophthalmology (1994), JB Lippincott Company, Philadelphia 1-36
3. Reddy M., Sharma S., and Rao G.N. Corneal ulcer. In: Dutta L.C. (Ed). Modern Ophthalmology. second ed. (2000), Jaypee Brothers Medical Publishers, New Delhi, India 200-216
4. Bourcier T., Thomas F., Borderie V., Chaumeil C., and Laroche L. Bacterial keratitis: predisposing factors clinical and microbiological review of 300 cases. Br. J. Ophthalmol. 87 (2000) 834-838
5. O'Brien T.P. Bacterial keratitis. In: Krachmer J.H., Mannis M.J., and Holland E.J. (Eds). Cornea: Cornea and External Diseases; Clinical Diagnosis and Management (1997), Mosby, St. Louis, USA 1139-1189
6. Tuft S.J., and Matheson M. In vitro antibiotic resistance in bacterial keratitis in London. Br. J. Ophthalmol. 84 (2000) 687-691
7. Dajcs J.J., Moreau J.M., Stroman D.W., Schlech B.A., Ke T.L., Thibodeaux B.A., Girgis D.O., Caballero A.R., and O'Callaghan R.J. The effectiveness of tobramycin and Ocuflox® in a prophylaxis model of Staphylococcus keratitis. Curr. Eye Res. 23 (2001) 60-63
8. Parkin B., Turner E., Moore E., and Cook S. Bacterial keratitis in the critically ill. Br. J. Ophthalmol. 81 (1997) 1060-1063
9. Cheng K.H., Leung S.L., Hoekman H.W., Beekhuis W.H., Mulder P.G.H., Geerards A.J.M., and Kijlstra A. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet 354 (1999) 181-185
10. Ostler H.B. Disease of cornea. In: Mitchell C.W. (Ed). Disease of the External Eye and Adnexa (1993), Williams & Wilkins, Baltimore, USA 137-252
11. Schaefer F., Bruttin O., Zografos L., and Guex-Crosier Y. Bacterial keratitis: a prospective clinical and microbiological study. Br. J. Ophthalmol. 85 (2001) 842-847
12. O'Brien T.P. Management of bacterial keratitis: beyond exorcism towards consideration of organism and host factors. Eye 17 (2003) 957-974
13. Limberg M.B. A review of bacterial keratitis and bacterial conjunctivitis. Am. J. Ophthalmol. 112 (1991) 2S-9S
14. McNeil M.M., and Brown J.M. The medically important aerobic actinomycetes: epidemiology and microbiology. Clin. Microb. Rev. 7 (1994) 358-417
15. Sridhar M.S., Sharma S., Reddy M.K., Mruthyunjay P., and Rao G.N. Ocular Nocardia infections with special emphasis on the cornea. Survey Ophthalmol. 45 (2001) 361-378
16. Roth H.W., Leimbeck R., Sonneschein B., Anger C.B., and Weber S. The effective antibacterial spectrum of sulfacetamide. Klin. Monatsbl. Augenheilkd. 200 (1992) 182-186
17. Chrai S.S., and Robinson J.R. Ocular evaluation of methylcellulose vehicle in rabbits. J. Pharm. Sci. 68 (1984) 1218-1223
18. Durrani A.M., Farr S.J., and Kellaway I.W. Influence of molecular weight and formulation pH on the precorneal clearance rate of hyaluronic acid in the rabbit eye. Int. J. Pharm. 118 (1995) 243-250
19. Harmann V., and Keipert S. Physico-chemical, in vitro and in vivo characterisation of polymers for ocular use. Pharmazie 57 (2000) 628-631
20. Pritchard W.H. The role of hydrogen bonding in adhesion. Aspects Adhes. 6 (1971) 11
21. Park H., and Robinson J.R. Physico-chemical properties of water insoluble polymers important to mucin/epithelial adhesion. J. Control. Release 2 (1985) 47-57
22. Satoh K., Takayama K., Machida Y., Suzuki Y., Nakagaki M., and Nagai T. Factors affecting the bioadhesive properties of tablets consisting of hydroxypropyl cellulose and carboxy vinyl polymers. Chem. Pharm. Bull. 37 (1989) 1366-1368
23. Thermes F., Rozier A., Plazonnet B., and Grove J. Bioadhesion: the effect of polyacrylic acid on the ocular bioavailability of timolol. Int. J. Pharm. 81 (1992) 59-65
24. Zimmer A., and Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv. Drug Deliv. Rev. 16 (1995) 61-73
25. Alonso M.J., and Sanchez A. The potential of chitosan in ocular drug delivery. J. Pharm. Pharmacol. 55 (2003) 1451-1463
26. Fresta M., Panico A.M., Bucolo C., Giaanavola C., and Puglisi G. Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir. J. Pharm. Pharmacol. 51 (1999) 565-576
27. Law S.L., Huang K.J., and Chiang C.H. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J. Control. Release 63 (2000) 135-140
28. Fresta M., Fontana G., Bucolo C., Cavallaro G., Giammona G., and Puglisi G. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanospheres-encapsulated acyclovir. J. Pharm. Sci. 90 (2001) 201-207
29. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Deliv. Rev. 57 (2005) 1595-1639
30. De T.K., Bergey E.J., Chung S.J., Rodman D.J., Bharali D.J., and Prasad P.N. Polycarboxylic acid nanoparticles for ophthalmic drug delivery: an ex vivo evaluation with human cornea. J. Microencapsul. 21 (2004) 841-855
31. Aggarwal D., and Kaur I.P. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int. J. Pharm. 290 (2005) 155-159
32. Sezer A.D., Cevher E., Hatipoglu F., Ogurtan Z., Bas A.L., and Akbuga J. The use of fucosphere in the treatment of superficial partial thickness burns in rabbits. Eur. J. Pharm. Biopharm. 69 (2008) 189-198
33. Stjemschantz J., and Astin M. Anatomy and physiology of the eye: physiological aspects of ocular drug therapy. In: Edman P. (Ed). Biopharmaceutics of Ocular Drug Delivery (1993), CRC Press, Boca Raton, FL, USA 1-26
34. National Research Council (NRC), Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington, DC, USA, 1996.
35. Rhee M.K., Kowalski R.P., Romanowski E.G., Mah F.S., Ritterband D.C., and Gordon Y.J. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Am. J. Ophthalmol. 138 (2004) 226-230
36. Romanowski E.G., Mah F.S., Yates K.A., Kowalski R.P., and Gordon Y.J. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model. Am. J. Ophthalmol. 139 (2005) 867-877
37. Cevher E., Orhan Z., Mulazimoglu L., Sensoy D., Alper M., Yi{dotless}ldi{dotless}z A., and Ozsoy Y. Characterization of biodegradable chitosan microspheres containing vancomycin and treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with prepared microspheres. Int. J. Pharm. 317 (2006) 127-135
38. Giunchedi P., Conte U., Chetoni P., and Saettone M.F. Pectin microspheres as ophthalmic carriers for piroxicam: evaluation in vitro and in vivo in albino rabbits. Eur. J. Pharm. Sci. 9 (1999) 1-7
39. Orhan Z., Cevher E., Mulazimoglu L., Gurcan D., Alper M., Araman A., and Ozsoy Y. The preparation of ciprofloxacin hydrochloride-loaded chitosan and pectin microspheres. Their evaluation in an animal osteomyelitis model. J. Bone Joint Surg. 88-B (2006) 270-275
40. Vidgren P., Vidgren M., Arppe J., Hakuli T., Laine E., and Paronen P. In vitro evaluation of spray-dried mucoadhesive microspheres for nasal administration. Drug Dev. Ind. Pharm. 18 (1992) 581-597
41. Cuña M., Alonso M.J., and Torres D. Preparation and in vivo evaluation of mucoadhesive microparticles containing amoxycillin-resin complexes for drug delivery to the gastric mucosa. Eur. J. Pharm. Biopharm. 51 (2001) 199-205
42. Gurny R., Ibrahim H., Aebi A., Buri P., Wilson C.G., and Washington N. Design and evaluation of controlled release systems for the eye. J. Control. Release 6 (1987) 367-373
43. Hui H.W., and Robinson J.R. Ocular delivery of progesterone using a bioadhesive polymer. Int. J. Pharm. 26 (1985) 203-213
44. Johnston T.P., Dias C.S., Mitra A.K., and Alur H. Mucoadhesive polymers in ophthalmic drug delivery. In: Mitra A.K. (Ed). Ophthalmic Drug Delivery Systems (2003), Marcel Dekker Inc., New York, USA 409-436
45. A. Gottschalk, The Chemistry and Biology of Sialic Acid and Related Substances, Cambridge University Press, London.
46. Mikos A.G., and Peppas N.A. Systems for controlled release of drug. V. Bioadhesive systems. S.T.P. Pharm. Sci. 2 (1986) 705-716
47. Lehr C.M., Lee Y.H., and Lee V.H.L. Improved ocular penetration of gentamicin by mucoadhesive polymer in the pigmented rabbit. Invest. Ophthalmol. Vis. Sci. 35 (1994) 2809-2814
48. Greaves J.L., and Wilson C.G. Treatment of diseases of the eye with mucoadhesive delivery systems. Adv. Drug Deliv. Rev. 11 (1993) 349-383
49. Dudinski O., Finnin B.C., and Reed B.L. Acceptability of thickened eye drops to human subjects. Curr. Ther. Res. 33 (1983) 322-337
50. Zignani M., Tabatabay C., and Gurny R. Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels. Adv. Drug Deliv. Rev. 16 (1995) 51-69
51. Safwat S.M., and Al-Kassas R.S. Evaluation of gentamicin-Eudragit microspheres as ophthalmic delivery systems in inflamed rabbit's eye. S.T.P. Pharm. Sci. 12 (2002) 357-361